One systematic review showed no reduced risk of cancer of the prostate, breast, kidney, uterus, ovary, bladder or melanoma, but did show a protective effect for metformin with CRC, liver, pancreas, oesophagus and stomach. Metformin was also used as adjuvant therapy in cancer patients, and most of the cancer clinical trials of metformin use the same doses typically used to treat diabetes. Summary Preclinical evidence suggests that metformin appears to inhibit the proliferation and growth of certain types of cancer. Metformin is also being studied for its effect on thyroid as it appears to reduce the risk of goiters, thyroid nodules, and thyroid cancer. When You Should Take It It is recommended that people take Metformin with meals as this both increases its absorption in the stomach and reduces side effects—stomach cramps, diarrhea, and nausea. Summary. Stomach cancer is found among people who take Metformin, especially for people who are female, 60+ old , have been taking the drug for 6 - 12 months, also take medication Vicodin, and have High blood pressure. Call your doctor or get emergency medical help if you have unusual muscle pain, trouble breathing, stomach pain, dizziness, feeling cold, or feeling very weak or tired. Before taking this medicine You should not use metformin if you are allergic to it, or if you have: Metformin side effects are caused because metformin interferes with the absorption, synthesis, transportation, storage, metabolism and excretion of certain nutrients. This happens due to long term use of the drug metformin. Metformin reduces self-renewal gastric cancer stem cells (CSCs) capacities. • Metformin decreases the pool of gastric CSCs. • Metformin is able to induce differentiation of gastric CSCs. Let us understand the drug Metformin in detail and study different forms of metformin, its uses and common metformin side effects along with how to deal with them. Me Me You can address them through diet, Vitamin B12, CoQ10, and exercise. Interactions. Metformin in combination with the drugs against high pressure suppresses the growth of cancer cells. As we know, and as has been stated by the studies preformed on the global scale, slowing down of the cancer cells proliferation is the most difficult task the contemporary medicine encounters whatsoever. The aim of our study was to evaluate the anti-tumoural effect of metformin on gastric cancer in vitro and in vivo and especially, to determine whether this molecule could target the gastric CSCs. Metformin effects were evaluated on the proliferation and tumourigenic properties of the gastric CSCs from patient-derived primary tumour xenografts (PDXs) and cancer cell lines (MKN45, AGS and MKN74.